论文部分内容阅读
目的 研究氧氟沙量缓释药物植片在玻璃体腔释药过程 ,为外伤性眼内炎等玻璃体腔感染的有效药物治疗提供实验依据。方法 根据体外释药数据 ,选取含氧氟沙星 10 %、分子量为 12 ,5 5 0的聚乳酸缓释植片 ,植入兔眼玻璃体腔 ,采用高效液相法作多点眼内药浓检测。结果 观测 42天 ,玻璃体内氧氟沙量浓度为 0 65～ 4 2 2 μg/ml ,其中 2 8天在一般最小抑菌浓度范围 ( 0 2 0～ 2 0 μg/ml)以上 ( >2 0 μg/ml) ,其有效释药时间延长 2 0余倍。结论 该缓释药物植片在兔眼玻璃体内药代学数据符合眼内炎抗菌药物治疗要求。
Objective To study the drug release process of oxyfonic sustained-release drug in the vitreous cavity and provide experimental evidence for the effective drug treatment of traumatic endophthalmitis and other vitreous cavity infections. Methods According to the drug release data in vitro, polylactic acid (SLA) sustained-release implants containing 10% ofloxacin and molecular weight of 12.55 were selected and implanted into the vitreous chamber of rabbits. The intraocular drug concentration was measured by high performance liquid chromatography . Results After 42 days of observation, the concentration of oxalosis in the vitreous was 0 65-4 2 2 μg / ml, of which 28 days were above the minimum inhibitory concentration (0 2 0 ~ 20 μg / ml) (> 20 μg / ml), its effective release time prolonged 20 times. Conclusion The intravitreal pharmacokinetic data of the sustained release drug implant in rabbit eyes meet the requirements of endophthalmitis antimicrobial therapy.